WTO's COVID deal: more vaccine ‘enabler’ than IP waiver?

After several days and sleepless nights, members of the World Trade Organisation (WTO) finally agreed several key trade initiatives last week, including one that promises to suspend patent protection of the COVID-19 vaccines.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Governments may have to reserve 20% of vaccines: WHO

2 February 2023 Draft WHO agreement aims at more robust and fairer response to future pandemics | 20% of tests and drugs would go to the organisation, including 10% donated.

Americas

WTO waiver decision postponed

20 December 2022 Members agreed to a partial waiver of patent protection for COVID-19 vaccines | Latest delay follows a similar decision by the US | WTO accused of “failure”.

Americas

US supports delay to COVID waiver extension

8 December 2022 Extension is “pathetic” says vaccine charity coalition | US Trade Representative says extra time will “help the world make a more informed decision” about the controversial patent waiver.

More features

Killing the golden goose of US drug innovation (Part I): Follow the money

GSK escalates mRNA COVID-19 vaccine dispute

An update on patenting in Ukraine, Russia and Eurasia

UPC sees rising small molecule litigation with Pfizer in the hot seat

Why the Caribbean cannabis economy is ripe for IP protection

The right formula: Minimising the cost of chemical and pharma patents

Overcoming refusal of TMs containing ingredient names in China

Why the PTAB’s new expedited filing dates for AIA petitions is positive

WTO's COVID deal: more vaccine ‘enabler’ than IP waiver?

More on this story

Editor's picks

Editor's picks

More features